Literature DB >> 26288677

Incentives to Repurpose Existing Drugs for Orphan Indications.

Annette K Kwok1, Fabian M Koenigbauer1.   

Abstract

The Orphan Drug Act has been successful in providing incentives to find cures for orphan diseases. However, many orphan diseases are still without cure. Therefore, the 114th Congress has introduced the 21st Century Cures Act and the Orphan Product Extension Now Accelerating Cures and Treatment Act of 2015 to further provide incentives to innovators to repurpose existing drugs for treatment of these orphan diseases. However, these bills are currently pending and their incentives might not go far enough.

Year:  2015        PMID： 26288677      PMCID： PMC4538444          DOI： 10.1021/acsmedchemlett.5b00276

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  8 in total

1.  Incentives for Starting Small Companies Focused on Rare and Neglected Diseases.

Authors:  Sean Ekins; Jill Wood
Journal:  Pharm Res       Date:  2015-12-14       Impact factor: 4.200

Review 2.  Drug repurposing for antimicrobial discovery.

Authors:  Maya A Farha; Eric D Brown
Journal:  Nat Microbiol       Date:  2019-03-04       Impact factor: 17.745

3.  Large-scale computational drug repositioning to find treatments for rare diseases.

Authors:  Rajiv Gandhi Govindaraj; Misagh Naderi; Manali Singha; Jeffrey Lemoine; Michal Brylinski
Journal:  NPJ Syst Biol Appl       Date:  2018-03-13

Review 4.  Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?

Authors:  Vitor Ennes-Vidal; Rubem Figueiredo Sadock Menna-Barreto; Marta Helena Branquinha; André Luis Souza Dos Santos; Claudia Masini D'Avila-Levy
Journal:  Parasitology       Date:  2016-11-21       Impact factor: 3.234

5.  Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.

Authors:  Viviana Giannuzzi; Rosa Conte; Annalisa Landi; Serena Antonella Ottomano; Donato Bonifazi; Paola Baiardi; Fedele Bonifazi; Adriana Ceci
Journal:  Orphanet J Rare Dis       Date:  2017-04-03       Impact factor: 4.123

6.  The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.

Authors:  Mohua Chakraborty Choudhury; Gayatri Saberwal
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

Review 7.  The Diverse Calpain Family in Trypanosomatidae: Functional Proteins Devoid of Proteolytic Activity?

Authors:  Vítor Ennes-Vidal; Marta Helena Branquinha; André Luis Souza Dos Santos; Claudia Masini d'Avila-Levy
Journal:  Cells       Date:  2021-02-01       Impact factor: 6.600

Review 8.  Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.

Authors:  Natalie K Boyd; Chengwen Teng; Christopher R Frei
Journal:  Front Cell Infect Microbiol       Date:  2021-05-17       Impact factor: 5.293
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.